MA46951A - Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes - Google Patents

Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Info

Publication number
MA46951A
MA46951A MA046951A MA46951A MA46951A MA 46951 A MA46951 A MA 46951A MA 046951 A MA046951 A MA 046951A MA 46951 A MA46951 A MA 46951A MA 46951 A MA46951 A MA 46951A
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
composition intended
opioid dependence
prevent opioid
prevent
Prior art date
Application number
MA046951A
Other languages
English (en)
French (fr)
Inventor
John Davis
Catherine Stehman-Breen
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA46951A publication Critical patent/MA46951A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MA046951A 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes MA46951A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29

Publications (1)

Publication Number Publication Date
MA46951A true MA46951A (fr) 2019-10-09

Family

ID=60766150

Family Applications (2)

Application Number Title Priority Date Filing Date
MA046951A MA46951A (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
MA45890A MA45890B2 (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA45890A MA45890B2 (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Country Status (18)

Country Link
US (2) US10736961B2 (https=)
EP (1) EP3548082B1 (https=)
JP (1) JP7071975B2 (https=)
KR (1) KR20190090820A (https=)
CN (1) CN110072549A (https=)
AU (1) AU2017366870B2 (https=)
BR (1) BR112019010331A2 (https=)
CA (1) CA3045116A1 (https=)
CL (1) CL2019001385A1 (https=)
CO (1) CO2019005247A2 (https=)
EA (1) EA201991283A9 (https=)
IL (1) IL266640B (https=)
MA (2) MA46951A (https=)
MX (1) MX2019006013A (https=)
MY (1) MY200701A (https=)
PH (1) PH12019501087A1 (https=)
WO (1) WO2018102294A1 (https=)
ZA (1) ZA201902967B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210043624A (ko) * 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023212586A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
MX2010001395A (es) 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies

Also Published As

Publication number Publication date
CN110072549A (zh) 2019-07-30
CO2019005247A2 (es) 2019-05-31
JP2019535716A (ja) 2019-12-12
MX2019006013A (es) 2019-10-14
PH12019501087A1 (en) 2019-08-19
US10736961B2 (en) 2020-08-11
US11491222B2 (en) 2022-11-08
US20180147280A1 (en) 2018-05-31
EA201991283A1 (ru) 2019-09-30
ZA201902967B (en) 2024-10-30
JP7071975B2 (ja) 2022-05-19
IL266640B (en) 2022-09-01
EA201991283A9 (ru) 2019-11-27
EP3548082A1 (en) 2019-10-09
MA45890B2 (fr) 2022-10-31
WO2018102294A1 (en) 2018-06-07
CL2019001385A1 (es) 2019-07-26
KR20190090820A (ko) 2019-08-02
BR112019010331A2 (pt) 2019-10-22
CA3045116A1 (en) 2018-06-07
AU2017366870B2 (en) 2024-09-19
MA45890A1 (fr) 2020-02-28
IL266640A (en) 2019-07-31
US20210060159A1 (en) 2021-03-04
EP3548082B1 (en) 2024-05-15
MY200701A (en) 2024-01-11
AU2017366870A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
EP3493799A4 (en) CANNABIS
EP3493798A4 (en) CANNABIS
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
DK3529248T3 (da) Farmaceutiske sammensætninger
EP3513809A4 (en) MEDICAL COMPOSITION
EP3319606A4 (en) PHARMACEUTICAL COMPOUND
MA46334A (fr) Composition pharmaceutique liquide
PT3297605T (pt) Composições farmacêuticas tópicas
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3532029T3 (da) Flydende farmaceutisk sammensætning
DK3655017T3 (da) Farmaceutisk sammensætning
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
DK3529240T3 (da) Farmaceutiske forbindelser
MA43705A (fr) Formulation pharmaceutique
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
EP3207149C0 (en) PHARMACEUTICAL COMPOSITION WITH IMPROVED STABILITY
MA42840A (fr) Composé pharmaceutique
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
EP3402470A4 (en) STABLE PHARMACEUTICAL COMPOSITION
MA47516A (fr) Composition pharmaceutique
EP3459369A4 (en) PHARMACEUTICAL COMPOSITION WITH LACTOBACILLUS SP. KCCM 11826P STRAIN FOR PREVENTING HYPERPHOSPHATMA AND TREATING CHRONIC KIDNEY DISEASE AND HEALTH FUNCTIONAL FOOD
EP3383371A4 (en) PHARMACEUTICAL FORMULATION
EP3603655A4 (en) COMPOSITION FOR DEGRADING OPIOID PEPTIDES
BR112016030507A2 (pt) Compostos relacionados à vitamina d, composição farmacêutica, e kit